Bisnafide mesylate

Drugs of the Future

Volumn 21, Issue 3, 1996, Pages 239-244

  Robinson, Casey P ^b   Robinson, Kent A ^b   Castaner J ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISNAFIDE MESYLATE; DOXORUBICIN;

ANIMAL CELL; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; LUNG CARCINOMA; MOUSE; NONHUMAN; SHORT SURVEY; TUMOR CELL;

EID: 0029945099     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.03.345057     Document Type: Short Survey

References (24)

1. Sun, J.-H. (The DuPont Merck Pharm. Co.). Bis-naphthalimides containing amino-acid derived linkers as anticancer agents. EP 506008, EP 577753, JP 94506229, US 5206249, WO 9217453.
2. Noonan, K.E., Beck, C., Holzmayer, T.A. et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990, 87: 7160-4.
3. McRipley, R.J., Burns-Horwitz, P.E., Czerniak, P.M. et al. Efficacy of DMP 840: A novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. Cancer Res 1994, 54: 159-64.
4. Chen, S -F., Behrens, D.L., Behrens, C.H et al. XB596: A promising bis-naphthalimide anti-cancer agent. Anti-Cancer Drugs 1993, 4: 447-57.
5. Kirshenbaum, M.R., Chen, S.-F., Behrens, C.H. et al. (R,R)-2,2′-[1,2-Ethanediylbis[imino(1-methyl-2, 1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione]dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Cancer Res 1994, 54: 2199-206.
6. Houghton, P.J., Cheshire, P.J., Hallman, J.C. III, Gross, J.L., McRipley, R.J., Sun, J.H., Behrens, C.H., Dexter, D.L., Houghton, J.A. Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers Cancer Chemother Pharmacol 1994, 33: 265-72.
7. Papp, L.M., Kirshenbaum, M.R., Chen, S.-F., Stafford, M.M., Fredericks, J.R., Behrens, D.L., Behrens, C.-H., Sun, J.-H., Gross, J.L. Mechanistic and anti-proliferative activities of DMP 840, a novel bis-naphthalimide antitumor agent. Proc Amer Assoc Cancer Res 1993, 34: Abst 2288.
8. Stafford, M.M., Kirshenbaum, M.R., Elliott, K.J. et al. DNA binding characteristics of DMP 840, a novel bis-naphthalimide antitumor agent. Proc Amer Assoc Cancer Res 1993, 34: Abst 2292.
9. Cobb, P.W., Degen, D.R., Clark, G.M., Chen, S.F., Kuhn, J.G., Gross, J.L., Kirshenbaum, M.R, Sun, J.H., Burns, H.A. III, Von Hoff, D.D. Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units. J Natl Cancer Inst 1994, 86: 1462-5.
10. Czerniak, P., McRipley, R., Behrens, C.H. et al. Magnitude and duration of antitumor response caused by DMP 840, a novel bis-naphthalimide antitumor agent, against human solid tumor xenografts in vivo. Proc Amer Assoc Cancer Res 1993, 34: Abst 2289.
11. LoRusso, P.M., Demchik, L., Polin, L., Jones, J., Knight, J., Behrens, C.H.. Sun, J.H., McRipley, R., Gross, J.L., Corbett, T.H. Antitumor activity of DMP840. Proc Amer Assoc Cancer Res 1993, 34: Abst 2265.
12. McRipley, R., Behrens, C.H., Burns-Horwitz, P. et al. Evaluation of DMP 840, a novel antitumor agent, in murine and human tumor models in vivo. Proc Amer Assoc Cancer Res 1993, 34: Abst 2291.
13. Houghton, P.J., Cheshire, P.J., Hallman, J., Sun, J.-H., Behrens, C.H., McRipley, R., Gross, J.L. Evaluation of DMP 840, a novel antitumor agent in xenografts derived from adult and childhood malignancies. Proc Amer Assoc Cancer Res 1993, 34: Abst 2193.
14. Henderson, N.L, Sternberg, N.L. Use of bacterial mutants to study mechanism of action of the anticancer agent, DMP840. Proc Amer Assoc Cancer Res 1994, 35: Abst 2329.
15. Arthaud, L.A., Frith, C.H., Meunier, P.C., Neubauer, R.H. DMP 840 does not increase the frequency of spontaneous tumors in CD-1 mice. Proc Amer Assoc Cancer Res 1994, 35: Abst 2755.
16. Neubauer, R.H., Gamba-Vitalo, C., Frith, C.H., Meunier, P.C., Arthaud, L. A. Effect of DMP 840 on the development of lymphoproliferative diseases in CD-1 nude mice. Proc Amer Assoc Cancer Res 1994, 35: Abst 2754.
17. Cobb, P., Kuhn, J., Degen, D., Dzubow, J., Chen, S., Nibbelink, D., Finizio, M., Burris, H., Von Hoff, D. DMP 840: Preclinical studies of a new bisnaphthalimide Proc Amer Soc Clin Oncol 1993, 12: Abst 422.
18. Slichenmyer, W., Finizio, M., Sartorius, S. et al. Phase I and pharmacologic study of DMP 840 as a single infusion every three weeks. Proc Amer Soc Clin Oncol 1994, 13: Abst 362.
19. O'Reilly, S., Rowinsky, E.K., Grochow, L. et al. Phase I and pharmacologic study of DMP 840 as a 24 hour infusion in patients with solid tumors. Proc Amer Soc Clin Oncol 1995, 14: Abst 1529.
20. Pieniaszek, H., Lai, C.-M., Slichenmyer, W. et al. Clinical pharmacokinetics (PK) of DMP 840, a novel bis-naphthalimide anticancer agent. J Clin Pharmacol 1994, 34: Abst 35.
21. Arthaud, L.E., Springer, J.K. Preclinical toxicity of the anticancer agent DMP 840 in mice, rats and dogs. Proc Amer Assoc Cancer Res 1993, 34: Abst 2290.
22. Cobb, P., Burris, H., Finizio, M. et al. Phase I trial and pharmacokinetic study of a new bis-naphthalimide, DMP 840, given daily × 5. Proc Amer Soc Clin Oncol 1994, 13: Abst 429.
23. Cobb, P., Burris, H., Drengler, R. et al. Phase I trial of DMP 840 given as a 120-hour continuous infusion every 28 days. Proc Amer Soc Clin Oncol 1995, 15: Abst 1577.
24. In development: New medicines for cancer. Pharmaceutical Research and Manufacturers of America 1995, May.